Malignant hyperthermia is a rare, life-threatening reaction that occurs in genetically susceptible individuals when they are exposed to certain general anesthetic gases or the muscle relaxant succinylcholine. It causes a rapid, uncontrolled rise in body temperature, muscle rigidity, a fast heart rate and rapid breakdown of muscle tissue, driven by abnormal calcium release inside muscle cells, most often linked to mutations in the RYR1 gene. Without prompt treatment it can be fatal, but it is managed effectively with the drug dantrolene, which blocks the abnormal calcium release, along with cooling and supportive care. Because it is inherited, family members of an affected person are often advised to undergo testing before undergoing general anesthesia themselves.
Facts
Classification
ICD-10 ChapterXIX: Injury, Poisoning and Certain Other Consequences of External Causes 2 Communicable or Non-communicable Transmission Route Causative Agent
Causative Agent (category) First Described Connections
Sources
1. Wikipedia: Malignant hyperthermia
Article text
The syndrome was first recognized in Royal Melbourne Hospital, Australia in an affected family by Denborough et al. in 1962.
Lead section, disease-category statement
Malignant hyperthermia (MH) is a type of severe reaction that occurs in response to particular medications used during general anesthesia, among those who are susceptible.
Lead section, body-system statement
Symptoms include muscle rigidity, fever, and a fast heart rate.
Lead section, transmission-route statement
Malignant hyperthermia (MH) is a type of severe reaction that occurs in response to particular medications used during general anesthesia, among those who are susceptible.
Lead section, body-system statement (cardiovascular)
Symptoms include muscle rigidity, fever, and a fast heart rate.
View the Source2. Wikipedia: ICD-10
WikipediaList of chapters, Chapter XIXQuote, List of chapters, Chapter XIX
Injury, poisoning and certain other consequences of external causes
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.